DeBary
DeBary
DeBary, Florida, United States25 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, chronic cutaneous lupus erythematosus, connective tissue disorder, cutaneous lupus erythematosus, discoid lupus erythematosus, immune system disorder, skin disorder, subacute cutaneous lupus erythematosus, systemic lupus erythematosus | Active, not recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT05531565 | |
| A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, cutaneous lupus erythematosus, discoid lupus erythematosus, immune system disorder, skin disorder, systemic lupus erythematosus | Recruiting | Phase 3 | 2026-10-06 | NCT07355218 | |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, cutaneous lupus erythematosus, immune system disorder, skin disorder, systemic lupus erythematosus | Recruiting | Phase 2 | 2026-10-05 | NCT07260877 | |
| A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE) | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Enrolling by invitation | Phase 3 | 2026-10-05 | NCT05352919 | |
| A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, Nutritional and Metabolic Diseases, arthritic joint disease, arthropathy, gout, hereditary disease, inborn disorder of purine or pyrimidine metabolism, inborn errors of metabolism, metabolic disease, musculoskeletal system disorder, rheumatic disorder | Recruiting | Phase 2 | 2026-09-28 | NCT07535034 | |
| A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06878404 | |
| A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06807424 | |
| A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05197049 | |
| Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica | Skin and Connective Tissue Diseases, connective tissue disorder, muscle tissue disorder, musculoskeletal system disorder, polymyalgia rheumatica, rheumatic disorder | Recruiting | Phase 4 | 2026-09-22 | NCT07286214 | |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-09-22 | NCT06676319 | |
| Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 2 | 2026-09-22 | NCT05039840 | |
| A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 3 | 2026-09-15 | NCT05648500 | |
| Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Enrolling by invitation | Phase 3 | 2026-09-11 | NCT06475742 | |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2026-09-03 | NCT06883305 | |
| Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Not applicable | 2026-08-31 | NCT07108166 | |
| Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 2 | 2026-07-21 | NCT05966480 | |
| Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough | Refractory or Unexplained Chronic Cough | Active, not recruiting | Phase 2 | 2026-06-11 | NCT06504446 | |
| Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 3 | 2026-04-28 | NCT05843643 | |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis | Fibrosis, Hemic and Lymphatic Diseases, Hypersensitivity, Delayed, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, diffuse scleroderma, immune system disorder, interstitial lung disease, lung disorder, lymphatic system disorder, lymphoproliferative syndrome, musculoskeletal system disorder, pulmonary fibrosis, respiratory system disorder, rheumatic disorder, rheumatoid arthritis, sarcoidosis, skin disorder, systemic sclerosis | Active, not recruiting | Phase 3 | 2026-04-23 | NCT06025578 | |
| Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 4 | 2026-04-16 | NCT05097287 | |
| Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 3 | 2026-04-13 | NCT04524611 | |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-03-24 | NCT06003426 | |
| A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 3 | 2026-02-10 | NCT04895241 | |
| A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | Skin and Connective Tissue Diseases, connective tissue disorder, dermatomyositis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, polymyositis, skin disorder | Active, not recruiting | Phase 2 | 2025-09-25 | NCT06284954 | |
| Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, Hyperuricemia, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arthritic joint disease, arthropathy, gout, hereditary disease, inborn disorder of purine or pyrimidine metabolism, inborn errors of metabolism, metabolic disease, musculoskeletal system disorder, rheumatic disorder | Active, not recruiting | Phase 2 | 2024-11-14 | NCT05690204 |